Chapter 24: Commercial Exploitation of Fungal Metabolites and Mycelia

The transition to higher-yielding strains like Penicillium chrysogenum enabled large-scale fermentation, establishing the foundation for modern antibiotic production. Subsequent fungal discoveries expanded this pharmaceutical arsenal, including cephalosporins from Acremonium species and griseofulvum from Penicillium griseofulvum for antifungal therapy, while the chapter emphasizes ongoing challenges posed by bacterial resistance mechanisms. A major breakthrough came with cyclosporine, an immunosuppressive metabolite produced by Tolypocladium niveum, which selectively inhibits T-helper lymphocyte activation and revolutionized organ transplantation while opening therapeutic pathways for autoimmune conditions including rheumatoid arthritis and multiple sclerosis. Beyond pharmaceuticals, fungi serve as metabolic factories for industrial compounds including organic acids such as citric acid and gluconic acid, vitamins like riboflavin, and plant growth regulators including gibberellic acid. The chapter details fungal enzyme production for diverse applications ranging from juice clarification using amylases to leather processing with proteases, detergent formulation with lipases, and textile treatment with cellulases. Emerging biotechnological frontiers include anaerobic rumen fungi producing powerful cellulases and genetically modified fungi engineered to express mammalian proteins including insulin and tissue plasminogen activator. The discussion extends to sustainable materials development, highlighting how Pestalotiopsis microspora degrades polyurethane plastics and how mycelium-based cultivation generates biodegradable alternatives to petroleum-derived packaging and foam insulation. This chapter illustrates fungi as renewable biological systems capable of producing pharmaceuticals, industrial enzymes, specialty chemicals, and sustainable materials, positioning fungal biotechnology as central to addressing medical needs and environmental challenges.